Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Betsy Hoza is active.

Publication


Featured researches published by Betsy Hoza.


Journal of the American Academy of Child and Adolescent Psychiatry | 2009

The MTA at 8 Years: Prospective Follow-up of Children Treated for Combined-Type ADHD in a Multisite Study

Brooke S. G. Molina; Stephen P. Hinshaw; James M. Swanson; L. Eugene Arnold; Benedetto Vitiello; Peter S. Jensen; Jeffery N. Epstein; Betsy Hoza; Lily Hechtman; Howard Abikoff; Glen R. Elliott; Laurence L. Greenhill; Jeffrey H. Newcorn; Karen C. Wells; Timothy Wigal; Robert D. Gibbons; Kwan Hur; Patricia R. Houck

OBJECTIVES To determine any long-term effects, 6 and 8 years after childhood enrollment, of the randomly assigned 14-month treatments in the NIMH Collaborative Multisite Multimodal Treatment Study of Children With Attention-Deficit/Hyperactivity Disorder (MTA; N = 436); to test whether attention-deficit/hyperactivity disorder (ADHD) symptom trajectory through 3 years predicts outcome in subsequent years; and to examine functioning level of the MTA adolescents relative to their non-ADHD peers (local normative comparison group; N = 261). METHOD Mixed-effects regression models with planned contrasts at 6 and 8 years tested a wide range of symptom and impairment variables assessed by parent, teacher, and youth report. RESULTS In nearly every analysis, the originally randomized treatment groups did not differ significantly on repeated measures or newly analyzed variables (e.g., grades earned in school, arrests, psychiatric hospitalizations, other clinically relevant outcomes). Medication use decreased by 62% after the 14-month controlled trial, but adjusting for this did not change the results. ADHD symptom trajectory in the first 3 years predicted 55% of the outcomes. The MTA participants fared worse than the local normative comparison group on 91% of the variables tested. CONCLUSIONS Type or intensity of 14 months of treatment for ADHD in childhood (at age 7.0-9.9 years) does not predict functioning 6 to 8 years later. Rather, early ADHD symptom trajectory regardless of treatment type is prognostic. This finding implies that children with behavioral and sociodemographic advantage, with the best response to any treatment, will have the best long-term prognosis. As a group, however, despite initial symptom improvement during treatment that is largely maintained after treatment, children with combined-type ADHD exhibit significant impairment in adolescence. Innovative treatment approaches targeting specific areas of adolescent impairment are needed.


Journal of Developmental and Behavioral Pediatrics | 2001

Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers

Peter S. Jensen; Stephen P. Hinshaw; James M. Swanson; Laurence L. Greenhill; C. Keith Conners; L. Eugene Arnold; Howard B. Abikoff; Glen R. Elliott; Lily Hechtman; Betsy Hoza; John S. March; Jeffrey H. Newcorn; Joanne B. Severe; Benedetto Vitiello; Karen C. Wells; Timothy Wigal

In 1992, the National Institute of Mental Health and 6 teams of investigators began a multisite clinical trial, the Multimodal Treatment of Attention-Deficit Hyperactivity Disorder (MTA) study. Five hundred seventy-nine children were randomly assigned to either routine community care (CC) or one of three study-delivered treatments, all lasting 14 months. The three MTA treatments-monthly medication management (usually methylphenidate) following weekly titration (MedMgt), intensive behavioral treatment (Beh), and the combination (Comb)-were designed to reflect known best practices within each treatment approach. Children were assessed at four time points in multiple outcome. Results indicated that Comb and MedMgt interventions were substantially superior to Beh and CC interventions for attention-deficit hyperactivity disorder symptoms. For other functioning domains (social skills, academics, parent-child relations, oppositional behavior, anxiety/depression), results suggested slight advantages of Comb over single treatments (MedMgt, Beh) and community care. High quality medication treatment characterized by careful yet adequate dosing, three times daily methylphenidate administration, monthly follow-up visits, and communication with schools conveyed substantial benefits to those children that received it. In contrast to the overall study findings that showed the largest benefits for high quality medication management (regardless of whether given in the MedMgt or Comb group), secondary analyses revealed that Comb had a significant incremental effect over MedMgt (with a small effect size for this comparison) when categorical indicators of excellent response and when composite outcome measures were used. In addition, children with parent-defined comorbid anxiety disorders, particularly those with overlapping disruptive disorder comorbidities, showed preferential benefits to the Beh and Comb interventions. Parental attitudes and disciplinary practices appeared to mediate improved response to the Beh and Comb interventions.


Journal of the American Academy of Child and Adolescent Psychiatry | 2001

Impairment and Deportment Responses to Different Methylphenidate Doses in Children With ADHD: The MTA Titration Trial

Laurence L. Greenhill; James M. Swanson; Benedetto Vitiello; Mark Davies; Walter Clevenger; Min Wu; L. Eugene Arnold; Howard B. Abikoff; Oscar G. Bukstein; C. Keith Conners; Glen R. Elliott; Lily Hechtman; Stephen P. Hinshaw; Betsy Hoza; Peter S. Jensen; Helena C. Kraemer; John S. March; Jeffrey H. Newcorn; Joanne B. Severe; Karen C. Wells; Timothy Wigal

OBJECTIVE Results of the NIMH Collaborative Multisite Multimodal Treatment Study of Children With Attention-Deficit/Hyperactivity Disorder (MTA) were analyzed to determine whether a double-blind, placebo-controlled methylphenidate (MPH) titration trial identified the best MPH dose for each child with attention-deficit/hyperactivity disorder (ADHD). METHOD Children with ADHD assigned to MTA medication treatment groups (n = 289) underwent a controlled 28-day titration protocol that administered different MPH doses (placebo, low, middle, and high) on successive days. RESULTS A repeated-measures analysis of variance revealed main effects for MPH dose with greater effects on teacher ratings of impairment and deportment (F3 = 100.6, n = 223, p = .0001; effect sizes 0.8-1.3) than on parent ratings of similar endpoints (F3 = 55.61, n = 253, p = .00001; effect sizes 0.4-0.6). Dose did not interact with period, dose order, comorbid diagnosis, site, or treatment group. CONCLUSIONS The MTA titration protocol validated the efficacy of weekend MPH dosing and established a total daily dose limit of 35 mg of MPH for children weighing less than 25 kg. It replicated previously reported MPH response rates (77%), distribution of best doses (10-50 mg/day) across subjects, effect sizes on impairment and deportment, as well as dose-related adverse events.


Journal of Abnormal Child Psychology | 2000

Anxiety as a predictor and outcome variable in the multimodal treatment study of children with ADHD (MTA).

John S. March; J Swanson; Arnold Le; Betsy Hoza; C. K. Conners; Stephen P. Hinshaw; Lily Hechtman; Helena C. Kraemer; Laurence L. Greenhill; Howard B. Abikoff; Elliott Lg; Peter S. Jensen; Jeffrey H. Newcorn; Benedetto Vitiello; Joanne B. Severe; Karen C. Wells; William E. Pelham

Initial moderator analyses in the Multimodal Treatment Study of Children with ADHD (MTA) suggested that child anxiety ascertained by parent report on the Diagnostic Interview Schedule for Children 2.3 (DISC Anxiety) differentially moderated the outcome of treatment. Left unanswered were questions regarding the nature of DISC Anxiety, the impact of comorbid conduct problems on the moderating effect of DISC Anxiety, and the clinical significance of DISC Anxiety as a moderator of treatment outcome. Thirty-three percent of MTA subjects met DSM-III-R criteria for an anxiety disorder excluding simple phobias. Of these, two-thirds also met DSM-III-R criteria for comorbid oppositional-defiant or conduct disorder whereas one-third did not, yielding an odds ratio of approximately two for DISC Anxiety, given conduct problems. In this context, exploratory analyses of baseline data suggest that DISC Anxiety may reflect parental attributions regarding child negative affectivity and associated behavior problems (unlike fearfulness), particularly in the area of social interactions, another core component of anxiety that is more typically associated with phobic symptoms. Analyses using hierarchical linear modeling (HLM) indicate that the moderating effect of DISC Anxiety continues to favor the inclusion of psychosocial treatment for anxious ADHD children irrespective of the presence or absence of comorbid conduct problems. This effect, which is clinically meaningful, is confined primarily to parent-reported outcomes involving disruptive behavior, internalizing symptoms, and inattention; and is generally stronger for combined than unimodal treatment. Contravening earlier studies, no adverse effect of anxiety on medication response for core ADHD or other outcomes in anxious or nonanxious ADHD children was demonstrated. When treating ADHD, it is important to search for comorbid anxiety and negative affectivity and to adjust treatment strategies accordingly.


Journal of Consulting and Clinical Psychology | 1993

Separate and combined effects of methylphenidate and behavior modification on boys with attention deficit-hyperactivity disorder in the classroom

William E. Pelham; Caryn L. Carlson; Susan E. Sams; Gary Vallano; M. Joanne Dixon; Betsy Hoza

This study evaluated the separate and combined effects of behavior modification and 2 doses of methylphenidate (MPH; 0.3 and 0.6 mg/kg) compared with baseline (no behavior modification and a placebo) on the classroom behavior and academic performance of 31 ADHD (attention deficit-hyperactivity disorder) boys attending a summer treatment program. Results revealed significant effects of both interventions, with the mean effect size of medication being more than twice as great as that of behavior modification. Relatively small incremental value was gained by the higher dose of medication or the addition of behavior modification, compared with the effects of the low dose of MPH. In contrast, the addition of either dose of MPH resulted in improvement beyond the effects of behavior modification alone. These group effects reflected those obtained in analyses of individual differences. Furthermore, comparisons of individual responsiveness showed that boys who responded to one treatment also responded to the other.


Journal of Abnormal Child Psychology | 2000

Parenting and family stress treatment outcomes in Attention Deficit Hyperactivity Disorder (ADHD): An empirical analysis in the MTA study

Karen C. Wells; Jeffrey Epstein; Stephen P. Hinshaw; Ck Conners; John Klaric; Hb Abikoff; Ann Abramowitz; Le Arnold; Gr Elliott; Laurence L. Greenhill; Lily Hechtman; Betsy Hoza; Pj Jensen; John S. March; William E. Pelham; Linda J. Pfiffner; Joanne B. Severe; James M. Swanson; Benedetto Vitiello; Timothy Wigal

Parenting and family stress treatment outcomes in the MTA study were examined. Male and female (579), 7–9-year-old children with combined type Attention Deficit Hyperactivity Disorder (ADHD), were recruited at six sites around the United States and Canada, and randomly assigned to one of four groups: intensive, multi-faceted behavior therapy program alone (Beh); carefully titrated and monitored medication management strategy alone (MedMgt); a well-integrated combination of the two (Comb); or a community comparison group (CC). Treatment occurred over 14 months, and assessments were taken at baseline, 3, 9, and 14 months. Parenting behavior and family stress were assessed using parent-report and child-report inventories. Results showed that Beh alone, MedMgt alone, and Comb produced significantly greater decreases in a parent-rated measure of negative parenting, Negative/Ineffective Discipline, than did standard community treatment. The three MTA treatments did not differ significantly from each other on this domain. No differences were noted among the four groups on positive parenting or on family stress variables. Results are discussed in terms of the theoretical and empirically documented importance of negative parenting in the symptoms, comorbidities and long-term outcomes of ADHD.


Developmental Psychology | 1997

Inhibition in Boys With Attention Deficit Hyperactivity Disorder as Indexed by Heart Rate Change

J. Richard Jennings; Maurits W. van der Molen; William E. Pelham; Kay Brock Debski; Betsy Hoza

A stop signal paradigm in combination with heart rate measures were used to test the hypothesis of deficient inhibitory processing in boys with attention deficit hyperactivity disorder (ADHD). The authors measured the inhibitory process initiated by a stop signal by observing its success, its latency using a horse race model, and its impact on the timing of the heartbeat. Boys with ADHD performed well and showed appropriate psychophysiological changes. Inhibition latencies were longer in the boys with ADHD, particularly those with concurrent oppositional defiant disorder, than in the controls. Cardiac evidence suggested that greater preparation was associated with inhibition failures in controls, but not in the boys with ADHD. Boys with ADHD seem capable of attending carefully to control responses, but this control appears less effective and arguably is more effortful than in other boys.


Journal of Consulting and Clinical Psychology | 2006

Treatment-Related Changes in Objectively Measured Parenting Behaviors in the Multimodal Treatment Study of Children With Attention-Deficit/Hyperactivity Disorder

Karen C. Wells; Terry C. Chi; Stephen P. Hinshaw; Jeffery N. Epstein; Linda J. Pfiffner; Marie S. Nebel-Schwalm; Elizabeth B. Owens; L. Eugene Arnold; Howard Abikoff; C. Keith Conners; Glen R. Elliott; Laurence L. Greenhill; Lily Hechtman; Betsy Hoza; Peter S. Jensen; John S. March; Jeffrey H. Newcorn; William E. Pelham; Joanne B. Severe; James M. Swanson; Benedetto Vitiello; Timothy Wigal

The present study examined treatment outcomes for objectively measured parenting behavior in the Multimodal Treatment Study of Children with Attention-Deficit/Hyperactivity Disorder (ADHD). Five hundred seventy-nine ethnically and socioeconomically diverse children with ADHD-combined type (ages 7.0-9.9 years) and their parent(s) were recruited at 6 sites in the United States and Canada and randomly assigned to 1 of 4 treatment groups for 14 months of active intervention: medication management (MedMgt), intensive behavior therapy, combination of the 2 (Comb), or a community-treated comparison (CC). Baseline and posttreatment laboratory observations of parent-child interactions were coded by observers blind to treatment condition. Comb produced significantly greater improvements in constructive parenting than did MedMgt or CC, with effect sizes approaching medium for these contrasts. Treatment effects on child behaviors were not significant. The authors discuss the importance of changes in parenting behavior for families of children with ADHD and the need for reliable and objective measures in evaluating treatment outcome.


Journal of Attention Disorders | 1999

The Multidimensional Anxiety Scale for Children (MASC): Confirmatory factor analysis in a pediatric ADHD sample:

John S. March; Ck Conners; G. Arnold; Jeffrey Epstein; James D.A. Parker; Stephen P. Hinshaw; Hb Abikoff; Brooke S.G. Molina; Karen C. Wells; Jh Newcorn; Sabrina Schuck; William E. Pelham; Betsy Hoza

While considerable attention has been paid to discriminating attention-deficit/hyperactivity and anxiety disorders, there are as yet no published confirmatory factor analytic studies of any self-report anxiety scale in ADHD youth. The Multidimensional Anxiety Scale for Children (MASC) is a 39-item, 4-point Likert self-report scale that robustly represents the factor structure of anxiety in children aged 8 to 18 years. Using confirmatory factor analytic methods, the present paper reports a replication of the four-factor measurement model for the MASC in a large sample of ADHD youth aged 7 to 10 years. The fit indices proved to be comparable to those obtained in the MASC clinical and non-clinical (normative) samples. Clinically, therefore, this report strengthens confidence that the MASC is a valid measure of anxiety in diverse populations. With respect to research, it provides supporting evidence that results obtained using the MASC in the MTA and other research studies reflect valid estimates of anxiety in those samples.


Archives of General Psychiatry | 1999

A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder

Pj Jensen; Le Arnold; Je Richters; Jb Severe; Donald Vereen; Benedetto Vitiello; E Schiller; Stephen P. Hinshaw; Gr Elliott; Ck Conners; Kc Wells; John S. March; J Swanson; Timothy Wigal; Dennis P. Cantwell; Hb Abikoff; J Hechtman; Ll Greeenhill; Jh Newcorn; We Pelham; Betsy Hoza; Hk Kraemer

Collaboration


Dive into the Betsy Hoza's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Timothy Wigal

University of California

View shared research outputs
Top Co-Authors

Avatar

Benedetto Vitiello

University Hospitals of Cleveland

View shared research outputs
Top Co-Authors

Avatar

John S. March

Johns Hopkins University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

William E. Pelham

Florida International University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jeffrey H. Newcorn

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge